A randomised controlled trial to assess the antithrombotic effects of aspirin in type 1 diabetes: role of dosing and glycaemic control.

ABSTRACT:

Background

The enhanced thrombotic milieu in diabetes contributes to increased risk of vascular events. Aspirin, a key antiplatelet agent, has inconsistent effects on outcomes in diabetes and the best dosing regimen remains unclear. This work investigated effects of aspirin dose and interaction with glycaemia on both the cellular and protein components of thrombosis.

Methods

A total of 48 participants with type 1 diabetes and 48 healthy controls were randomised to receive aspirin 75 or 300 mg once-daily (OD) in an open-label crossover study. Light transmittance aggregometry and fibrin clot studies were performed before and at the end of each treatment period.

Results

Aspirin demonstrated reduced inhibition of collagen-induced platelet aggregation (PA) in participants

SUBMITTER: Parker WAE 

PROVIDER: S-EPMC8684134 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature